
    
      BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their
      growth. The Phase II trial is designed to study the effectiveness of BCX-1777 in treating
      patients who have recurrent or refractory advanced T-cell leukemia.
    
  